Expression and copy number profiles from histologically normal duct tissue near tumors suggest a "field of cancerization" may exist in epithelial cells around cancer.
Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.
The researchers are developing a province-wide registry of targeted sequencing test results for the study that will be made available to other cancer researchers.
With exome sequences, RNA sequences, and methylation profiles, investigators uncovered differences between radiation-induced and sporadic forms of meningioma.
The initiatives are being funded with C$24 million over two years and will focus on acute leukemia, immuno-oncology, and brain, ovarian, and pancreatic cancer.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
